CF Biomarker study
The ultimate goal of this study is to identify a simple blood or sputum test reflective of disease activity in the lung to help personalize the care of individuals with cystic fibrosis (CF). More specifically, the purpose of this pilot study is to identify a molecule (protein or ribonucleic acid) in the blood and/or sputum test that can be used in clinical practice to diagnose pulmonary exacerbations (or lung flare-ups) earlier and to monitor response to exacerbation treatment. This study will also collect information on your symptoms, lung function, and sputum microbiology when you are clinically stable and throughout the course of treatment (if and when you experience a pulmonary exacerbation). Enrollment remains open for the Biomarkers study.